Triplet maintenance therapy of olaparib, pembrolizumab and bevacizumab in women with BRCA wild-type, platinum-sensitive recurrent ovarian cancer: the multicenter, single-arm phase II study OPEB-01/APGOT-OV4
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Triplet maintenance therapy of olaparib, pembrolizumab and bevacizumab in women with BRCA wild-type, platinum-sensitive recurrent ovarian cancer: the multicenter, single-arm phase II study OPEB-01/APGOT-OV4 ; volume:14 ; number:1 ; day:6 ; month:9 ; year:2023 ; pages:1-8 ; date:12.2023
Nature Communications ; 14, Heft 1 (6.9.2023), 1-8, 12.2023
- Creator
-
Kim, Yoo-Na
Park, Boram
Kim, Jae Weon
Kim, Byoung Gie
Kim, Sang Wun
Kim, Hee Seung
Choi, Chel Hun
Lim, Myong Cheol
YL Ngoi, Natalie
SP Tan, David
Lee, Jung-Yun
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41467-023-40829-2
- URN
-
urn:nbn:de:101:1-2024020210553446766310
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:29 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Kim, Yoo-Na
- Park, Boram
- Kim, Jae Weon
- Kim, Byoung Gie
- Kim, Sang Wun
- Kim, Hee Seung
- Choi, Chel Hun
- Lim, Myong Cheol
- YL Ngoi, Natalie
- SP Tan, David
- Lee, Jung-Yun
- SpringerLink (Online service)
Other Objects (12)
MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib
FSP1 inhibition enhances olaparib sensitivity in BRCA-proficient ovarian cancer patients via a nonferroptosis mechanism
Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial
Successful Combination of Olaparib and 225 Ac-Dotatate in a Patient with Neuroendocrine Tumor G3 and BRCA Mutation
Conversion surgery for BRCA-mutated pancreatic ductal adenocarcinoma with liver metastasis treated with platinum-based chemotherapy followed by olaparib
Pembrolizumab
Olaparib First-Line Maintenance Monotherapy in BRCA-Mutated Epithelial Ovarian Cancer: Descriptive Analysis of the First French Real-World Data Study
Clinical significance of germline breast cancer susceptibility gene (gBRCA) testing and olaparib as maintenance therapy for patients with pancreatic cancer
Triplet‐triplet Annihilation Dynamics of Naphthalene
Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY
BRCA 1 and BRCA 2 tumor suppressors protect against endogenous acetaldehyde toxicity
BRCA promoter methylation in sporadic versus BRCA germline mutation-related breast cancers
MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib
FSP1 inhibition enhances olaparib sensitivity in BRCA-proficient ovarian cancer patients via a nonferroptosis mechanism
Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial
Successful Combination of Olaparib and 225 Ac-Dotatate in a Patient with Neuroendocrine Tumor G3 and BRCA Mutation
Conversion surgery for BRCA-mutated pancreatic ductal adenocarcinoma with liver metastasis treated with platinum-based chemotherapy followed by olaparib
Pembrolizumab
Olaparib First-Line Maintenance Monotherapy in BRCA-Mutated Epithelial Ovarian Cancer: Descriptive Analysis of the First French Real-World Data Study
Clinical significance of germline breast cancer susceptibility gene (gBRCA) testing and olaparib as maintenance therapy for patients with pancreatic cancer
Triplet‐triplet Annihilation Dynamics of Naphthalene
Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY
BRCA 1 and BRCA 2 tumor suppressors protect against endogenous acetaldehyde toxicity
BRCA promoter methylation in sporadic versus BRCA germline mutation-related breast cancers
MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib
FSP1 inhibition enhances olaparib sensitivity in BRCA-proficient ovarian cancer patients via a nonferroptosis mechanism
Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial
Successful Combination of Olaparib and 225 Ac-Dotatate in a Patient with Neuroendocrine Tumor G3 and BRCA Mutation
Conversion surgery for BRCA-mutated pancreatic ductal adenocarcinoma with liver metastasis treated with platinum-based chemotherapy followed by olaparib
Pembrolizumab
Olaparib First-Line Maintenance Monotherapy in BRCA-Mutated Epithelial Ovarian Cancer: Descriptive Analysis of the First French Real-World Data Study
Clinical significance of germline breast cancer susceptibility gene (gBRCA) testing and olaparib as maintenance therapy for patients with pancreatic cancer
Triplet‐triplet Annihilation Dynamics of Naphthalene
Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY
BRCA 1 and BRCA 2 tumor suppressors protect against endogenous acetaldehyde toxicity